Emprumapimod hydrochloride |
カタログ番号GC70928 |
Emprumapimod hydrochlorideの口頭アクティブであり、選択剤p38αMAPK。
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
Emprumapimod hydrochloride (ARRY-797) inhibits LPS-induced IL-6 production in RPMI-8226 cell with an IC50 value of 100 pM[1].
Emprumapimod hydrochloride (ARRY-797) (30 mg/kg; p.o.) inhibits the expression of IL-6 (91%) and TNF-α (95%) in SCID-beige mice, inhibits the phosphorylation of p38 in RPMI-8226 xenografts, inhibits the growth of RPMI-8226 tumour (72%) in multiple myeloma (MM) xenograft models[1].
Emprumapimod hydrochloride (30 mg/kg; p.o.; twice daily for 4 weeks) prevents left ventricular (LV) dilatation and deterioration of fractional shortening (FS) in LmnaH222P/H222P mice[2].
References:
[1]. Wright D, et al. ARRY-797, a potent and selective inhibitor of p38 map kinase, inhibits LPS-induced IL-6 and in vivo growth of RPMI-8226 human multiple myeloma cells[J]. 2006.
[2]. Antoine Muchir, et al. Abnormal p38α mitogen-activated protein kinase signaling in dilated cardiomyopathy caused by lamin A/C gene mutation. Hum Mol Genet. 2012 Oct 1;21(19):4325-33.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *